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Abstract
High cholesterol and diabetes are major risk factors for atherosclerosis. Regression of ath-
erosclerosis is mediated in part by the Liver X Receptor (LXR) through the induction of
genes involved in cholesterol transport and efflux. In the context of diabetes, regression of
atherosclerosis is impaired. We proposed that changes in glucose levels modulate LXR-
dependent gene expression. Using a mouse macrophage cell line (RAW 264.7) and primary
bone marrow derived macrophages (BMDMs) cultured in normal or diabetes relevant high
glucose conditions we found that high glucose inhibits the LXR-dependent expression of
ATP-binding cassette transporter A1 (ABCA1), but not ABCG1. To probe for this mecha-
nism, we surveyed the expression of a host of chromatin-modifying enzymes and found that
Protein Arginine Methyltransferase 2 (PRMT2) was reduced in high compared to normal
glucose conditions. Importantly, ABCA1 expression and ABCA1-mediated cholesterol
efflux were reduced in Prmt2-/- compared to wild type BMDMs. Monocytes from diabetic
mice also showed decreased expression of Prmt2 compared to non-diabetic counterparts.
Thus, PRMT2 represents a glucose-sensitive factor that plays a role in LXR-mediated
ABCA1-dependent cholesterol efflux and lends insight to the presence of increased athero-
sclerosis in diabetic patients.
Introduction
Diabetes mellitus is characterized by accelerated atherosclerosis and higher risk for cardiovas-
cular diseases [1–4]. Atherosclerosis in diabetic patients is often associated with increased pla-
que macrophages and dyslipidemia [5]. Though diabetes is a complex multifactorial disease it
is notable that high blood glucose levels have been shown to be an independent risk factor for
atherosclerosis [1, 6–8]. We and others have established previously in mouse models that
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lowering cholesterol levels promotes the regression of atherosclerosis [9–11]. This is partly
mediated by the Liver X Receptor (LXR), a transcription factor that induces the expression of
genes involved in cholesterol transport and efflux, a process known as reverse cholesterol trans-
port [12–14].
LXRs (LXRα and LXRβ) are members of the nuclear receptor family of transcription factors
[15]. They form an obligate heterodimer with the retinoid X receptor (RXR) and, in response
to either receptor’s ligand, upregulate genes involved in cholesterol transport and efflux [16–
18]. In a mouse model of atherosclerosis regression, diabetic mice show less plaque reduction
compared to their normoglycemic counterparts despite equivalent serum lipid profiles [19].
We hypothesized that high glucose alters the repertoire of LXR regulated genes in macrophages
and predicted that changes in gene transcription and expression would inhibit their ability to
efficiently efflux cholesterol under diabetic conditions.
Macrophages respond to cholesterol accumulation by increasing the expression of ATP-
binding cassette transporter A1 (ABCA1), to promote the removal of cholesterol and other lip-
ids from the cell [14, 20–22]. ABCA1 is known to transfer cholesterol from macrophages to the
specific lipid-poor cholesterol acceptor, apolipoprotein A1 (APOAI) [14, 21]. In macrophages,
excess cholesterol leads to the formation of oxysterols, the natural ligands of LXR, which stimu-
late Abca1 expression [20]. We found that macrophages cultured under elevated glucose condi-
tions showed decreased LXR-dependent ABCA1 mRNA and protein levels. Importantly, this
led to a defect in ABCA1-mediated efflux to APOAI. In an effort to understand the mechanism
of this glucose-mediated transcriptional effect, we looked to processes known to modify the
chromatin landscape. Gene transcription is a dynamic process involving the conversion of
compact heterochromatin into transcription factor accessible euchromatin. Chromatin modifi-
cations of different classes (e.g. acetylation, methylation, ubiquitination, phosphorylation) pos-
itively or negatively impact gene expression and play an important role in gene regulation [23,
24]. We examined the expression of chromatin modifying enzymes in these cells and found
that the level of a protein arginine methyltransferase, PRMT2, was lower in macrophages in a
high glucose environment. This was also true in monocytes isolated from diabetic mice that
were generated using streptozotocin (STZ), a drug that targets and ablates the insulin-produc-
ing pancreatic beta cells [25]. In the absence of insulin, these mice are unable to appropriately
absorb sugar from the blood into tissues responsible for sugar metabolism, which leads to
excess levels of blood glucose. This mechanism of hyperglycemia simulates the Type 1 diabetic
condition. Given that PRMT2 was previously shown to act as a coactivator for other members
of the nuclear receptor family, we hypothesized that PRMT2 could serve as a regulator for
LXR-dependent gene expression [26, 27]. Using macrophages from mice lacking the PRMT2
gene, we found that the lack of PRMT2 mimicked the effects of high glucose. Macrophages
from mice lacking PRMT2 had decreased LXR-mediated upregulation of ABCA1 and a pro-
found defect in ABCA1-mediated cholesterol efflux to APOAI. Thus, PRMT2 represents a glu-
cose-sensitive factor that plays a role in LXR-mediated Abca1 expression and
ABCA1-dependent cholesterol efflux.
Materials and Methods
RAW264.7 cells ectopically expressing human LXRα
RAW264.7 cells stably expressing FLAG-tagged human LXRα (herein referred to as RAW
WT) previously described in [28] were maintained in Dulbecco's modified Eagle's medium
(DMEM, Gibco) with 10% fetal bovine serum (FBS) and 1% PenStrep (100 U/mL Penicillium
and 100ug/mL Streptomycin) in either 4.5 g/L D-glucose or 1 g/L D-glucose + 3.5 g/L L-glu-
cose (Sigma) as an osmotic control. Cells were maintained in these glucose conditions for a
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minimum of two weeks before being used and were cultured in 1% FBS overnight before exper-
iments. Cells were cultured in 5% CO2 atmosphere at 37°C. Cells were tested for mycoplasma
and were negative.
Bone marrow derived macrophages (BMDMs)
BMDMs were prepared from monocytes isolated from the tibia and femur of 6–10-week-old
C57BL/6 male mice. A total of 18 mice were used to perform the experiments. The animals
were maintained with a 12-hour light-dark cycle and had free access to food and water in a
pathogen-free facility with no more than 5 mice (< 25 g) per cage. Mice were euthanized by
CO2 followed by cervical dislocation in accordance with AVMA Guidelines for the Euthanasia
of Animals. Bone marrow cells were isolated, treated with red blood cell lysis buffer (Sigma)
and re-suspended in differentiation medium (DMEM with 1 g/L D-glucose + 3.5 g/L L-glucose
or 4.5 g/L D-glucose, 20% FBS, supplemented L-glutamine and 10 ng/μL macrophage colony-
stimulating factor (M-CSF) (PeproTech, Inc., Rocky Hill, NJ) and then were passed through a
70 μm filter to remove debris. Cells were maintained for 7 days in non-tissue coated plates to
promote their differentiation into unactivated (M0) macrophages. Cells were washed in PBS,
and re-plated in 1% FBS/DMEM. Culture of BMDMs was done in the absence of antibiotics.
This study was carried out in accordance with the recommendation in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health, and in agreement
with the Division of Laboratory Animal Resources (DLAR) at the NYU School of Medicine.
The protocol was approved by the NYU School of Medicine's Institutional Animal Care and
Use Committee (IACUC); approved protocol number 140203.
This study does not use human subjects.
Monocytes from STZ-treated mice
Mice (six) were injected intraperitoneally for five days with streptozotocin (STZ) (50 mg/kg,
Sigma-Aldrich) to induce diabetes or with citrate buffer (six) to serve as a control [25]. Leuko-
cyte subsets were identified from whole blood as previously described [29]. Monocytes were
identified as CD45hiCD115hi and Ly6-Chi using the following antibodies: APC anti-mouse Ly-
6G/Ly-6C (Gr-1), PE anti-mouse CD115, PE/Cy7 Anti-mouse CD45 (Biolegends).
Quantitative real time polymerase chain reaction (qRT-PCR)
Total RNA was extracted with the RNeasy Mini Kit (Qiagen) with an additional on-column
DNase digestion step. cDNA was synthesized from 1 μg of RNA using the First-Strand cDNA
Synthesis Kit for Real-Time PCR (USB) and random primer mix following the manufacturer's
instructions. cDNA was amplified with the SYBR Green Taq Ready Mix (USB) using MyiQ
Single-Color Real-Time PCR Detection System (Bio-Rad). Cyclophilin A was used as a nor-
malization control.
Primers
ABCA1: (qRT-PCR)
F: 5’-GGA CAT GCA CAA GGT CCT GA-30
R: 5’-CAG AAA ATC CTG GAG CTT CAA A-30
ABCG1: (qRT-PCR)
Forward: 5’-CCC TCA AAG CCG TAT CTG AC-30
Reverse: 5’-TTG ACA CCA TCC CAG CCT AC-30
Cyclophilin A: (qRT-PCR)
Forward: 5’-GGC CGA TGA CGA GCC C-30
Reverse: 5’-TGT CTT TGG AAC TTT GTC TGC AA-30
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Nascent ABCA1: (qRT-PCR)
Forward: 5’-TAGGATGAACCAACCACAGG-30
Reverse: 5’-GGGCACAATTCCACAAGAAT-30
PRMT2: (qRT-PCR)
Forward: 5’-AAGGTGCTCTTCTGGGACAA-30
Reverse: 5’-ATGATTCGACTTTGGCCTTG-30
ABCA1 LXRE (ChIP):
Forward: 5’-GGG GAA AGA GGG AGA GAA CAG-30
Reverse: 5’-GAA TTA CTG GTT TTT GCC GC-30
Preparation of cell extracts andWestern blotting
Macrophages were washed twice in ice-cold PBS prior to lysis (lysis buffer: 50 mMHEPES pH
7.6, 150 mMNaCl, 1 mM EDTA pH 8.0, 1 mM EGTA pH 8.0, 1 mM NaF, 1% Triton X-100,
10% glycerol) with protease inhibitor cocktail (1:100, Cell Signaling). Cellular debris was pel-
leted by centrifugation at 16,000 x g for 15 minutes at 4 oC. Supernatant was collected and pro-
tein concentrations were determined by the Bradford assay (Biorad). Samples were reduced
using Laemmli SDS loading buffer with beta-mercaptoethanol by incubation for 30 minutes at
room temperature.
Proteins were separated on 7.5% or 4–20% gradient polyacrylamide gels, and transferred to
PVDF membranes. Membranes were blocked with 5% BSA in TBS for 1 hour and incubated in
primary antibody (diluted in 5% BSA/TBS) at 4°C overnight. Antibodies used were anti-
ABCA1 (1:1,000, Novus 400–105), anti-HSP90 (1:500, BD 610419), anti-LXRα (1:1,000,
Abcam ab41902), anti-Myc (1:2,000, Cell Signaling 2276), and anti-dimethyl-arginine, asym-
metric (ASYM25) (1:1,000, EMDMillipore 07–414), and anti-BRG1 (1:1,000, Abcam ab4081).
Membranes were incubated with horseradish peroxidase-conjugated secondary antibody in
TBS-T at room temperature for 1 hour. The specific band was detected with a chemilumines-
cence assay (ECL detection reagents, Pierce) and recorded on X-ray film.
Mouse epigenetic chromatin modification enzymes PCR array
RNA (0.5 μg) from RAWWTmacrophages cultured under high or normal glucose was reverse
transcribed and 84 genes encoding enzymes known or predicted to modify DNA and histones
were analyzed using the Mouse Epigenetic Chromatin Modification Enzymes RT2 Profiler
PCR Array (Sabiosciences/Qiagen). The list of the genes analyzed is available at http://www.
sabiosciences.com/rt_pcr_product/HTML/PAMM-085A.html. Data analysis was performed
using the manufacturer’s web-based software package.
CpGmethylation assay
The EpiTect Methyl II PCR Assay (Sabiosciences/Qiagen) was used to evaluate the CpG meth-
ylation status of the Abca1 promoter region. Primers to the CpG island in the Abca1 promoter
(located at Chr4: 53172657–53173060) were purchased from Sabiosciences (EPMM107692-
1A). NIH 3T3 Mouse Genomic DNA (New England Biolabs N4004S) and CpGMethylated
NIH 3T3 Mouse Genomic DNA (N4005S) were used as controls. Genomic DNA was extracted
using the DNEasy kit (Qiagen). Genomic DNA was subjected to mock (no enzyme), methyla-
tion-sensitive (MSRE), methylation-dependent (MDRE), and double (MSRE and MDRE)
restriction enzyme digestion. After digestion, the remaining DNA was quantified by qPCR
with primers that amplify the Abca1 promoter CpG Island and the percentage unmethylated
and methylated DNA was determined relative to input.
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Prmt2-/- mice
Sperm from Prmt2-/- males on the C57BL/6J (B6) background were provided by Y. Herault
with permission from E. Nabel [30]. Mice were re-derived using in vitro fertilization of WT
C57BL/6 females. Heterozygote male and female offspring were used to generate Prmt2-/- mice
and wild-type littermate controls. A total of 10 Prmt2-/- and 10 control littermate male mice
were used in this study. The Prmt2tm1Enbl allele carries a G119X mutation and a neomycin cas-
sette replacing exons 4 and 5 and part of exon 6 [30]. Genotyping was performed by PCR using
primers: A: 50-CTGAGGTATTACCAGCAGACA-30; B: 50-CTCTCTGATGCAGGTCTAC-30;
C: 50-CCGGTGGATGTGGAATGTGT-30. Primers A and B identify the wild-type allele
(190-bp) and primers B and C identify the mutant allele (280-bp fragment).
Cholesterol efflux
BMDMs were loaded with 3H-cholesterol-Ac-LDL for 24 hours (0.5 μCi/ml 3H-cholesterol and
50 μg/ml Ac-LDL, [1,2-3H(N)]-Cholesterol, NET139250UC PerkinElmer), and equilibrated in
2 mg/mL BSA media overnight. Efflux to APOAI [50 μg/ml, human APOAI; Biomedical Tech-
nologies (BT-927)], or no acceptor (all using 2 mg/ml BSA media) was done for 24 hours.
Chromatin Immunoprecipitation (ChIP) assays
BMDMs were analyzed by ChIP as previously described [31]. Protein–DNA complexes were
cross-linked in 1% formaldehyde for 10 minutes at room temperature, followed by incuba-
tion in 0.125 M glycine for 5 minutes to quench the cross-linking reaction. Cells were washed
with 1x PBS twice and lysed in 5 mM PIPES at pH 8.0, 85 mM KCl, 0.5% NP-40 with protease
inhibitor (Cell Signaling). The cell lysate was centrifuged at 250 x g for 5 minutes at 4°C, and
the crude nuclear pellets were collected. Chromatin was sonicated into 500 bp—2,000 bp
fragments using the Bioruptor (Diagenode; Twin UCD-400). Immunoprecipitation was per-
formed overnight at 4°C using anti-LXRα (6 μg, Abcam ab41902) mouse monoclonal anti-
body or an equivalent amount of mouse IgG (Sigma-Aldrich). Protein G magnetic beads
(Invitrogen) were used to recover antibody complexes. The beads were washed in 100 mM
Tris at pH 7.5, 500 mM LiCl, 1% NP-40, 1% sodium deoxycholate and TE (10 mM Tris-HCl
at pH 7.5, 0.1 mM Na2EDTA) at 4°C. Following reversal of cross-linking, recovered DNA
was purified using PrepEase DNA Clean-Up Kit (USB). Cycle threshold values were normal-
ized to percent input and IgG.
Statistical analysis
Unless otherwise noted, all quantitative results are averages from at least three independent
experiments, and each sample was analyzed in triplicate. Data are expressed as the
mean ± SEM. Significance was determined using the two-tailed Student's t-test (, P< 0.05; ,
P< 0.01; , P< 0.001). All tests were performed using the Prism software (GraphPad Soft-
ware, Inc., La Jolla, CA). Western blots are representative of at least three independent
experiments.
Results
High glucose inhibits LXR-mediated induction of Abca1 and decreases
ABCA1-dependent cholesterol efflux
To investigate the effect of glucose levels on LXR-mediated gene expression in macrophages,
RAW cells stably expressing human LXRα (RAWWT) were maintained in diabetes relevant
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high glucose (25 mM D-glucose; 4.5 g/L D-glucose) or normal glucose (5.5 mM D-glucose;
1 g/L D-glucose supplemented with 3.5 g/L of L-glucose as an osmotic control) for two weeks.
Cells were treated with LXR/RXR ligands [TO901317 + 9cis retinoic acid: (T+9)] or DMSO as
a vehicle control for four hours and expression of the canonical LXR target gene Abca1 was
determined. Ligand treatment robustly induced Abca1 expression in RAWWT under normal
glucose conditions. This induction was significantly reduced in RAWWT cells cultured under
high glucose conditions (Fig 1A). Many processes, both transcriptional and post-transcrip-
tional, regulate steady state mRNA levels. To identify if the decrease in Abca1mRNA was tran-
scriptional, we also measured newly formed heteronuclear, or nascent, RNA. The change
observed in steady state mRNA was reflected in the nascent RNA transcripts of ABCA1: there
was less nascent Abca1mRNA production in high compared to normal glucose (Fig 1B). This
suggests that the differences in mRNA as a function of high glucose are due to a defect in LXR-
mediated transcription of the Abca1 gene.
To ensure that this is not a model-specific effect, we repeated the experiment using bone
marrow derived macrophages (BMDMs) differentiated in high or normal glucose, and treated
with LXR/RXR ligands. As in RAWWT cells, high glucose impaired ligand-mediated up-regu-
lation of Abca1 in BMDMs (Fig 2A), and this defect was reflected in the production of nascent
mRNA transcripts (Fig 2B). Importantly, the changes in mRNA translated to a decrease in
ABCA1 protein (Fig 2C). In contrast, the levels of LXRα protein were similar under both glu-
cose conditions (Fig 2D), which suggest that the changes in Abca1 expression are due to a
defect in LXR function as opposed to an effect of glucose on the expression of LXR itself. Inter-
estingly, the expression of Abcg1, another canonical LXR target gene, was not influenced by
changes in glucose levels (S1 Fig). This suggests an effect of glucose on an LXR cofactor that
confers a gene specific effect.
To assess the functional effect of high glucose-driven reduction in ABCA1 protein, we uti-
lized a cholesterol efflux assay. BMDMs cultured under normal or elevated glucose conditions
were loaded with 3H-cholesterol-Ac-LDL for 24 hours and their ability to efflux cholesterol
was assayed by the addition of the cholesterol acceptor APOAI to the media (Fig 3). Under
normal glucose conditions, robust APOAI-associated cholesterol efflux was observed when
compared to a control (no acceptor) condition that served to measure background efflux.
Notably, under high glucose conditions there was a significant reduction in ABCA1-mediated
efflux to APOAI (from 12.5% in normal glucose to 8.9% in high glucose, a 29.0% reduction).
This significant decrease in APOAI-directed efflux under high glucose was also seen in the
presence of the synthetic LXR/RXR ligands (T+9), which are known to further enhance
Fig 1. High glucose inhibits induction of Abca1 in RAWmacrophages.RAWWTmacrophages were
treated for four hours with 5 μM T + 1 μM 9cisRA (T+9) or DMSO vehicle control and steady state RNA (A)
and nascent RNA (B) transcripts of Abca1were profiled using qRT-PCR.Cyclophilin A was used for
normalization. Macrophages were cultured overnight in 1% FBS prior to treatment. Panel A represents an
average of five independent experiments and panel B represents an average of three independent
experiments. Error bars indicate the SEM. Significance is determined using the two-tailed Student's t-test
(*, P < 0.05, **, P<0.01, ***, P<0.001).
doi:10.1371/journal.pone.0135218.g001
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ABCA1 expression above that of Ac-LDL alone (normal glucose, 34.1%; high glucose, 20.3%; a
40.0% reduction) [32]. Thus, the reduction of ABCA1 gene expression under high glucose con-
ditions resulted in a functional decrease in ABCA1-dependent cholesterol efflux.
A subset of chromatin modifying enzymes is differentially expressed
under high glucose conditions
Our data suggest that the mechanism of varying ABCA1 expression as a function of glucose
levels is at the level of transcription. Previous studies have shown that hyperglycemia induces
genome wide changes in histone modifications and DNAmethylation in aortic endothelial
cells [33, 34]. We examined whether glucose concentration affected the expression of enzymes
that are known to regulate transcription by altering the modifications on DNA and histones in
macrophages. We cultured RAWWTmacrophages under high and normal glucose conditions,
extracted RNA and performed a qRT-PCR based array that examines the expression of 84
genes encoding enzymes that modify DNA and histones to regulate chromatin architecture. A
subset of enzymes showed changes in gene expression >2 fold under the different glucose con-
ditions. These included DNMT1, a maintenance DNAmethylation enzyme that displayed
increased expression in high glucose, and PRMT2, a type I protein arginine methyltransferase
that showed decreased expression in high glucose (Fig 4A). Type I enzymes asymmetrically
dimethylate a single terminal nitrogen residue of proteins [35]. Changes in CpG methylation
in aortic endothelial cells cultured under high glucose and recognition of PRMT2 as a
Fig 2. High glucose inhibits induction of Abca1 in BMDMs. Bonemarrow cells from C57BL/6 mice were
differentiated into macrophages under high (25 mM D-glucose) or normal (5.5 mMD-glucose + 19.5 mM L-
glucose) glucose. Prior to treatments, macrophages were cultured in 1% FBS overnight and then treated for
four hours with 5 μM T + 1 μM 9cisRA (T+9) or DMSO vehicle control and steady state RNA (A) and nascent
RNA (B) transcripts of Abca1were profiled using qRT-PCR. Cyclophilin Awas used for normalization. (C)
BMDMs were cultured and treated as in A for eight hours. Whole cell protein extracts were collected and
separated on a 7.5% polyacrylamide gel and were blotted for ABCA1. HSP90 was used as a loading control.
(D) Whole cell protein extracts collected from untreated BMDMs cultured under high and normal glucose
were separated as in (C) and blotted for LXRα. HSP90 was used as a loading control. The levels of LXRα and
HSP90 protein were quantitated by densitometry and presented below with normal glucose set to 1. The ratio
of panels A and B represent an average of three independent experiments. Error bars indicate the SEM.
Significance is determined using the two-tailed Student's t-test (*, P < 0.05, **, P<0.01, ***, P<0.001). (C)
and (D) are representative.
doi:10.1371/journal.pone.0135218.g002
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transcriptional coactivator for other nuclear receptors made these attractive candidates to
modulate ABCA1 expression as a function of glucose [26, 27, 33].
The level of DNMT1 is higher in RAWWT cells cultured under high glucose, potentially
conferring a repressive effect on transcription. There is also a CpG island in the Abca1 pro-
moter that is conserved between humans and mice [36]. Given DNMT1’s role in maintaining
CpG methylation throughout cell divisions and precedence for glucose leading to differences in
promoter methylation we tested if DNAmethylation of the Abca1 promoter is modulated by
glucose. We probed the methylation status of the CpG island of Abca1 in both RAWWT cells
and BMDMs cultured under high and normal glucose using methylation-dependent and-sensi-
tive restriction enzyme digests coupled with qPCR detection. To establish the efficacy of the
assay at the Abca1 CpG island we first examined genomic DNA from NIH 3T3 cells (a mouse
embryonic fibroblast cell line) that was enzymatically fully methylated with CpG methylase
and compared that to genomic DNA from control NIH 3T3 cells that should naturally have a
mixture of methylated and unmethyalted DNA. We observed from control NIH 3T3 cell DNA
that 12.40% of the Abca1 CpG island was unmethylated, while this number dropped to 0.13%
in the in vitro fully methylated DNA (Fig 4B). Thus the assay can effectively distinguish
between alterations in the DNA methylation status of the Abca1 promoter. Applying this assay
to genomic DNA from RAWWT cells and BMDMs cultured under high and normal glucose
conditions, we determined that RAWWT cells under high glucose had 99.96% unmethylated
CpGs while CpGs in RAWWT cells under normal glucose were 99.94% unmethylated. Simi-
larly BMDMs under high glucose were 99.93% unmethylated and BMDMs under normal glu-
cose were 99.91% unmethylated (Fig 4B). The Abca1 promoter was nearly fully unmethylated
in both cell types. This provides evidence that the CpG methylation status of Abca1 does not
govern the differences in Abca1 expression upon changes in glucose concentrations, and fur-
ther does not implicate a major role for DNMT1 in this process.
Fig 3. Cholesterol efflux to APOAI is inhibited by high glucose. Bone marrow cells from C57BL/6 mice
were differentiated into macrophages under high (25 mM D-glucose) or normal (5.5 mMD-glucose + 19.5 mM
L-glucose) glucose. BMDMs were loaded with 3H-cholesterol-Ac-LDL for 24 hours (0.5 μCi/mL 3H-cholesterol
and 50 μg/mL Ac-LDL), and then equilibrated in 2 mg/mL BSAmedia overnight. During equilibration cells
were treated with 5 μM T + 1 μM 9cisRA or DMSO vehicle control. Efflux to APOAI (50 μg/mL), or no acceptor
(all using 2 mg/mL BSAmedia) was done for eight hours. Specific efflux to APOAI is represented as a
percentage of total efflux over background efflux to no acceptor. Experiment was performed in quadruplicate.
Error bars represent SEM. Significance is determined using the two-tailed Student's t-test (*, P < 0.05,
**, P<0.01, ***, P<0.001).
doi:10.1371/journal.pone.0135218.g003
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Modulation of PRMT2 levels affects Abca1 expression
We were interested in the role of PRMT2 as a potential LXR regulator as it has been shown to
bind RXRα, the obligate binding partner of LXR [27]. Further, it has been shown to enhance
the transcriptional activity of other nuclear receptors, including AR and ERα [26, 27]. Signifi-
cantly, the decrease in Prmt2 expression under high glucose seen in RAWWT cells was also
observed in BMDMs at the mRNA (Fig 4C) and protein level (Fig 4D), which strengthens the
potential regulatory role of this enzyme in LXR function.
By homology PRMT2 has been classified as a Type I enzyme responsible for asymmetrically
dimethylating target proteins [35, 37]. However the in vivomethyltransferase activity of
PRMT2 has been thus far difficult to demonstrate [38]. Therefore, we examined globally for
the effect of PRMT2 on protein arginine methylation using an antibody that recognizes asym-
metric dimethylarginine. We examined protein extracts from BMDMs cultured in high vs. nor-
mal glucose as well as from Prmt2-/- macrophages and blotted for asymmetric
Fig 4. Chromatin-modifying enzymes expression and Abca1CpG islandmethylation under high and
normal glucose in macrophages. (A) RNA from RAWWT cells maintained under high (25 mM D-glucose)
or normal (5.5 mMD-glucose + 19.5 mM L-glucose) glucose was profiled using a qRT-PCR-based
chromatin-modifying array and expression changes in DNMT1 and PRMT2 are shown. (B) Epitect methyl
CpG assay was employed to examine the methylation status of the Abca1 promoter CpG island. NIH 3T3
Mouse Genomic DNA and CpGMethylated NIH 3T3 Mouse Genomic DNA were used as controls. Input DNA
was cleaved with methylation-sensitive and/or methylation-dependent restriction enzymes that digest
unmethylated and methylated DNA, respectively. Following digestion, remaining DNA was quantified by
qRT-PCR using primers that flank the CpG island. Percent methylation was determined by comparing the
amount digested by each enzyme to a mock digested sample. (C) RNA from BMDMs differentiated under
high (25 mM D-glucose) or normal (5.5 mM D-glucose + 19.5 mM L-glucose) glucose was extracted and
levels of Prmt2 were profiled using qRT-PCR. (D) PRMT2 protein expression in normal and high glucose.
Nuclear extract of BMDMs cultured as in C were blotted for PRMT2. Asterisk (*) represents a non-specific
band, which serves as a loading control. (E) Nuclear protein extracts from BMDMs from wild type (WT) mice
cultured in normal or high glucose and (F) whole cell extracts from BMDMs from wild type (WT) and Prmt2-/-
(KO) mice cultured under normal glucose were separated on a 4–20% gradient polyacrylamide gel and
immunoblotted with an antibody specific for asymmetric dimethyl arginine. BRG1 or HSP90, serve as nuclear
and whole-cell loading controls, respectively. Filled arrowheads represent asymmetric dimethyl arginine
immunoreactive proteins uniquely present in one of the conditions.
doi:10.1371/journal.pone.0135218.g004
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dimethylarginine. There were changes in methylated protein substrates from nuclear extracts
in wild type BMDMs cultured in high vs. normal glucose (Fig 4E) as well as specific changes in
the methylome from whole cell extracts between wild type and Prmt2-/- macrophages (Fig 4F).
This suggests that PRMT2 impacts protein arginine methylation and that a subset of proteins
appear differentially methylated as a function of glucose concentrations.
Having established that the levels of Prmt2mRNA are lower in macrophages cultured in
high glucose relative to normal glucose concentrations, we next investigated the effects of
increased levels of PRMT2 on LXR-dependent transcriptional activity in RAWmacrophages.
Transient overexpression of PRMT2 increased LXR/RXR ligand-dependent transcription of
Abca1 by about 50% (Fig 5A), without affecting Abcg1 expression (S1 Fig). By contrast, deple-
tion of PRMT2 in RAWWT cells using siRNAs specific to Prmt2 decreased ligand-dependent
Abca1mRNA expression (Fig 5B), consistent with PRMT2 possessing coregulatory function
for LXR at Abca1.
PRMTs have been shown to have histone-modifying functions, which affect transcription
factor binding [39]. Given this, we examined whether LXRα occupancy at the Abca1 promoter
was affected by Prmt2 deletion by chromatin immunoprecipitation (ChIP) of LXRα from
ligand-treated wild type vs. Prmt2-/- BMDMs. We did not observe any significant differences in
Fig 5. Prmt2 levels affect ligand-induced expression of Abca1. (A) Myc-DDK tagged PRMT2 in the
pCMV6 expression vector, or an empty pCMV6 (vector) control were transfected into RAWWT
macrophages. Overexpression was confirmed by blotting for the Myc-tag on PRMT2 or HSP90 as a loading
control. One day following transfection macrophages were cultured in 1% FBS overnight and then treated for
four hours with 5 μM T +1 μM 9cisRA (T+9) or DMSO vehicle control. RNA was extracted and Abca1mRNA
was measured by qRT-PCR. (B) PRMT2 levels were depleted in RAWWT cells using siRNA specific to
Prmt2 (siPRMT2) or scrambled siRNA as a control (siCON). Prmt2 depletion at the mRNA level was
confirmed by qRT-PCR. Following knockdown, cells were treated as in (A) and Abca1mRNA expression was
determined by qRT-PCR. Cyclophilin A was used as a control to normalize the qRT-PCR reactions.
Experiments were performed twice. Error bars represent SD of three technical replicates.
doi:10.1371/journal.pone.0135218.g005
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LXRα occupancy in Prmt2-/- compared to wild type cells (Fig 6). Similar results were observed
using an antibody that recognizes both LXRα and LXRβ (data not shown). This indicates that
the mechanism of the PRMT2 effect on LXR-mediated transcription of Abca1 is not a result of
differences in LXR occupancy at its binding site in the Abca1 promoter.
PRMT2 knockout macrophages show defects in upregulation of ABCA1
and decreased cholesterol efflux to APOAI
To further explore the role of PRMT2 in macrophage Abca1 expression and cholesterol efflux,
we carried out studies using BMDMs from Prmt2 deficient mice [30]. Prmt2-/- mice lack any
morphological or observable developmental defects [30]. As in previous experiments, BMDMs
were treated for four hours with LXR/RXR ligands (T+9). Compared to macrophages from
wild type littermate control mice, there was a pronounced reduction in Abca1mRNA induc-
tion (steady state and nascent) upon ligand stimulation (Fig 7A and 7B). This difference was
also evident at the protein level wherein Prmt2-/- macrophages had less ABCA1 than wild type
under ligand-stimulated conditions (Fig 7C). Importantly, LXR protein levels were equal in
wild type and Prmt2-/- macrophages, as was also seen in BMDMs cultured under high or nor-
mal glucose (Fig 7D and 7D). Abcg1 expression was not affected by depletion of PRMT2,
which is consistent with the observed lack of a glucose effect on Abcg1 expression (S1 Fig). We
also examined expression of the LXR target genes Srebp1c, Lpl, Apoe fromWT and Prmt2-/-
BMDMs treated with T+9 and found that they did not demonstrate a change in expression as a
function of PRMT2 (S2 Fig). This suggests that PRMT2 imparts gene-specific effects on LXR
target gene expression upon T+9 treatment.
We next assessed whether the reduction in ABCA1 in Prmt2-/- macrophages affected choles-
terol efflux. We found that there was a marked reduction in ABCA1-mediated cholesterol
efflux to APOAI in Prmt2-/- macrophages when compared to wild type littermate control mac-
rophages (Fig 8). This reduction in efflux was observed under normal glucose (WT, 23.7%
efflux; KO, 15.9% efflux) and in high glucose albeit to a lesser extent (WT, 18.6% efflux, KO,
13.2% efflux). This suggests PRMT2 is an important mediator of ABCA1 expression and
Fig 6. LXRα occupancy of Abca1 promoter LXRE.Chromatin was immunoprecipitated from wild type or
Prmt2-/- BMDMs treated for one hour with T+9 using an antibody specific to LXRα. Isotype matched IgG was
used as a control. Percent of precipitated DNA compared to total input DNA is shown. Data represent an
average of three independent experiments. Error bars represent SEM. Difference in LXRα occupancy
betweenWT and Prmt2-/- was not significant.
doi:10.1371/journal.pone.0135218.g006
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cholesterol efflux in primary macrophages, and that in addition to PRMT2-dependent effects,
high glucose imparts PRMT2-independent effects on cholesterol efflux.
Fig 7. Prmt2-/- BMDMsmimic the effect of high glucose on ABCA1. BMDMs from wild type (WT) or
Prmt2-/- (KO) mice were differentiated under normal glucose (5.5 mMD-glucose) conditions. Following
differentiation BMDMs were cultured in 1% FBS overnight and then treated for four hours with 5 μM T + 1 μM
9cisRA (T+9) or DMSO vehicle control. RNA was collected and steady state (A) or nascent (B) Abca1 levels
were determined by qRT-PCR. Cyclophilin A was used as a control. (C) Whole-cell protein extracts from
BMDMs cultured as in A and treated for eight hours with T+9 or DMSOwere separated on a 7.5%
polyacrylamide gel and immunoblotted for ABCA1 or HSP90 (loading control). (D) Whole-cell protein extracts
fromWT and KO BMDMs cultured under normal (5.5 mMD-glucose) glucose were separated on 7.5%
polyacrylamide gel and immunoblotted for LXRα. HSP90 was used as a loading control. (A) and (B) represent
averages of three independent experiments. Error bars indicate the SEM. Significance is determined using
the two-tailed Student's t-test (*, P < 0.05, **, P<0.01, ***, P<0.001).
doi:10.1371/journal.pone.0135218.g007
Fig 8. Efflux to APOAI is reduced in Prmt2-/- BMDMs.Wild type and Prmt2-/- BMDMs were differentiated
under high glucose (25 mMD-glucose) or normal glucose (5.5 mM D-glucose + 19.5 mM L-glucose) and
following differentiation were loaded with 3H-cholesterol-Ac-LDL for 24 hours (0.5 μCi/mL 3H-cholesterol and
50 μg/mL Ac-LDL), and then equilibrated in 2 mg/mL BSAmedia overnight. Efflux to APOAI (50 μg/mL), or no
acceptor (all using 2 mg/mL BSAmedia) was done for 24 hours. Specific efflux to APOAI is represented as a
percentage of total efflux over background efflux to no acceptor. Experiment was performed in quadruplicate.
Error bars represent SEM. Significance is determined using the two-tailed Student's t-test (*, P < 0.05,
**, P<0.01, ***, P<0.001).
doi:10.1371/journal.pone.0135218.g008
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Prmt2 levels are decreased in monocytes from diabetic mice
To determine if high glucose affects the expression of Prmt2 in vivo, monocytes (Ly6-Chi) from
C57BL/6, STZ-treated diabetic mice were isolated and Prmt2 expression was determined. As
expected, mice treated with STZ showed elevated blood glucose levels when compared to con-
trol-treated mice (Fig 9A). Importantly, compared to the non-diabetic control mice, diabetic
mice showed decreased expression of Prmt2 in Ly6-Chi monocytes (Fig 9B), the subset that
constitutes the largest fraction of monocytes recruited to mouse atherosclerotic plaques [40].
This suggests that hyperglycemia affects Prmt2 expression in vivo.
Discussion
This study explores the mechanism whereby diabetes-relevant high glucose modulates LXR-
dependent gene expression in macrophages as a prelude to understanding the clinical observa-
tion that diabetes exacerbates atherosclerosis. We demonstrate that in macrophage-like cell
lines and primary bone marrow derived macrophages cultured under high glucose there is a
selective reduction in the LXR-dependent induction of ABCA1 compared to cells cultured
under normal glucose concentrations upon activation by the combination of LXR/RXR ligands
T+9. This results in a functional effect of reduced ABCA1-dependent cholesterol efflux to
APOAI under high vs. normal glucose. We identified PRMT2 as a glucose-sensitive factor that
impacts LXR’s ability to regulate expression of ABCA1. PRMT2 mRNA expression and protein
levels are reduced when macrophages are cultured in high as compared to normal glucose.
Upon overexpression PRMT2 enhances Abca1 expression, whereas its depletion reduces Abca1
gene expression, with T+9 treatment. Interestingly we also found that Prmt2-/- macrophages
express less Abca1 and are less effective at ABCA1-mediated efflux to APOAI compared to
wild type macrophages with T+9 stimulation. Interestingly, the expression of Abca1 with indi-
vidual LXR/RXR ligands was less sensitive to changes in PRMT2 expression (S3 Fig), suggest-
ing that the action of PRMT2 is most relevant when both LXR and RXR are activated. These
findings support a role for PRMT2 in LXR-mediated regulation of ABCA1 expression and cho-
lesterol efflux as a function of glucose concentrations and ligands. Furthermore, this suggests a
potential molecular explanation behind enhanced atherosclerosis in diabetic patients. It will be
interesting to test additional LXR ligands for effects on the expression of Abca1 and other LXR
target genes as a function of PRMT2 expression in future studies.
Studies by Maio et al. identified genes differentially expressed in normal vs. high glucose in
human THP-1 cells by RNA-seq [41], but did not report PRMT2 as a gene that was down
Fig 9. Prmt2 expression is reduced in monocytes from diabetic mice. (A) Blood glucose levels were
measured from wild type and STZ-treated mice. (B) The level of PRMT2 in Ly6-Chi monocytes from wild type
and STZ-treated mice was profiled using qRT-PCR. Cyclophilin A was used as an endogenous control. Six
mice were used per condition. Error bars represent SEM. Significance is determined using the two-tailed
Student's t-test (*, P < 0.05).
doi:10.1371/journal.pone.0135218.g009
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regulated in high glucose. This could reflect differences in experimental design (acute high glu-
cose stimulation in their study vs. chronic high glucose treatment in ours) or cell type (undif-
ferentiated THP-1 monocytes vs. differentiated BMDMs). Studies in differentiated THP-1 cells
exposed to chronic high glucose concentrations could be done to examine this apparent
discrepancy.
PRMTs have been shown to modulate nuclear receptor activity through a number of mech-
anisms in addition to their histone-modifying functions. For example, the hepatocyte nuclear
factor (HNF4) is a nuclear receptor that is methylated by PRMT1, and methylation of the
HNF4 DNA-binding domain enhances HNF4’s affinity for its cognate binding site [42]. The
mechanism by which PRMT2 exerts its role on Abca1 upregulation by LXR is unknown.
PRMT2’s effect on Abca1 occurs only in the presence of ligand, suggesting that the presence of
increased PRMT2 alone is insufficient to increase Abca1 expression levels. This was also true in
PRMT2-mediated coactivation of ERα [27]. Regulation of LXR-dependent expression of Abca1
could be mediated via PRMT2’s ability to modify histone or non-histone proteins to affect
transcriptional activity. However, we did not observe alterations in the methylation of histone
H3 arginine 8 (H3R8), the putative target of PRMT2, at the Abca1 promoter in wild type or
Prmt2-/- macrophages, nor did we observe arginine methylation of LXRα as a function of
PRMT2 expression (data not shown). Interestingly, the impact of both glucose and PRMT2 is
LXR gene specific: for example, the LXR target gene Abcg1 is not affected by depletion of
PRMT2 nor is Abcg1 expression influenced by changes in glucose levels (S1 Fig).
Abca1 expression is controlled not only by LXRs but also by cAMP and protein kinase A-
dependent activation of CREB1. Elegant work from the Smith laboratory defined a cAMP
responsive element within the first intron of the mouse Abca1 locus that is bound by activated
CREB1 [43]. However, the finding that high glucose impacts the regulation of Abca1 via
CREB1 is unlikely given that CREB1 appears to be activated by high glucose [44], and would
therefore be predicted to increase rather than decrease Abca1 expression.
Recent molecular analysis of coregulator assembly at Abcg1 and Abca1 uncovered distinct
mechanisms of LXR regulation that may offer insight to the finding that the expression of
Abca1, but not Abcg1 is affected by high glucose. Jakobsson et al. found that the recruitment of
LXR to the Abcg1 promoter/enhancer unit is ligand-dependent and requires the coregulator G-
protein pathway suppressor 2 (GPS2), in conjunction with histone demethylases [KDM1
(LSD1), KDM3A (JHDM2A), and KDM4A (JMJD2A/JHDM3A)], that relaxes chromatin
structure to promote gene expression [45]. This is in contrast to Abca1 where LXR is pre-
bound to the Abca1 promoter in the absence of ligand along with GPS2, NCOR and HDAC2,
which serve to repress its expression. Whereas GPS2 is a coactivator at Abcg1 and is recruited
to the promoter upon ligand treatment, it is a co-repressor at Abca1 and is dismissed upon
ligand stimulation. Whether PRMT2 affects the activity of these or other coregulators in high
vs. normal glucose via arginine methylation to promote co-repressor or block co-activator
binding remains an open question. Indeed, factors that are differentially arginine methylated in
normal compared to high glucose (Fig 4E) could represent candidates that drive differential
gene expression of Abca1 as a function of glucose.
A clear mechanism for the differential gene sensitivity of Abca1 and Abcg1 toward PRMT2
could reflect differences in the occupancy of PRMT2 at one gene but not the other, which
could be addressed using ChIP assays. Unfortunately, we have been unable to specifically ChIP
PRMT2 with multiple commercial or in-house developed antibodies as we see similar “occu-
pancy” of PRMT2 at Abca1 in wild type and Prmt2-/- BMDMs. Thus, the available PRMT2
antibodies do not accurately reflect occupancy of PRMT2 via ChIP. To circumvent the lack of
a ChIP grade PRMT2 antibody we plan to engineer a FLAG-epitope into the endogenous
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PRMT2 protein using CRISPR-Cas9 technology, and then perform ChIP assays at Abca1 and
Abcg1 in normal and high glucose.
Little is known about what regulates Prmt2 expression. Examination of the human protein
atlas reveals expression of PRMT2 in 33 of 83 normal tissues including expression in bone mar-
row, lymph node, tonsils and spleen [46]. Predicted transcription factor binding sites in the
promoter region of Prmt2 indicates potential STAT, NFκB and cJun binding elements, and
interrogation of the ENCODE database reveals occupancy of STAT and Jun family members in
the Prmt2 promoter, but the functionality of these factors in Prmt2mRNA expression has not
been determined [47]. Establishing how Prmt2 is regulated and how glucose controls Prmt2
expression will be important for developing strategies to restore PRMT2 levels in the diabetic
setting.
Given our findings that macrophages show decreased ABCA1-mediated efflux upon reduc-
tion of PRMT2, studies that examine the effects of PRMT2 directly on atherosclerosis and dia-
betes are now warranted but beyond the scope of this study. We would predict that mice with
macrophages devoid of PRMT2 would be more prone to atherosclerosis due to their inability
to efficiently efflux cholesterol. Work performed by other groups suggests a somewhat different
scenario where deletion of PRMT2 has a protective effect with respect to atherosclerosis as
Prmt2-/- mice fed a high fat diet were resistant to weight gain and had favorable lipid profiles,
glucose tolerance tests and insulin levels [48]. However, this was done in the whole-body
PRMT2 knockout mouse and is likely a result of reduced food intake by changes in leptin sig-
naling due to PRMT2 loss in the brain. Thus, future studies directed at elucidating PRMT2 sub-
strates, regulation and in vivo function in macrophages would be crucial for understanding the
role PRMT2 plays in LXR-mediated regulation of Abca1 in diabetes and atherosclerosis.
Supporting Information
S1 Fig. Ligand stimulated induction of Abcg1 is unchanged by high glucose and PRMT2
levels. (A) Bone marrow cells from C57BL/6 mice were differentiated into macrophages under
high glucose (25 mMD-glucose) or normal glucose (5.5 mMD-glucose + 19.5 mM L-glucose).
Prior to treatments, macrophages were cultured in 1% FBS overnight and then treated for four
hours with 5 μMT + 1 μM 9cisRA or DMSO vehicle control and steady state RNA transcripts of
Abcg1 were profiled using qRT-PCR. (B) BMDMs from wild type and Prmt2-/- mice were cul-
tured and treated as in (A). (C) Myc-DDK tagged PRMT2 was transfected into RAWWTmac-
rophages; an empty vector (pCMV6) was used as a transfection control. Following transfection,
cells were switched to 1% FBS overnight and then treated for four hours with 5 μMT + 1 μM
9cisRA or DMSO vehicle control and RNA was profiled as in (A) Cyclophilin A was used as a
control for all qRT-PCR reactions. Panels A and B represent results from three independent
experiments. Error bars represent SEM. Significance is determined using the two-tailed Student's
t-test (, P< 0.05, , P<0.01, , P<0.001). Error bars represent SD of three technical repli-
cates.
(TIF)
S2 Fig. Ligand stimulated induction of Abcg1, Apoe, LPL and Srebp1c are unaffected by
PRMT2 levels. BMDMs from wild type and Prmt2-/- mice were cultured in normal glucose,
placed in 1% FBS overnight, and treated for four hours with 5 μMT+ 1 μM 9cisRA or DMSO
vehicle control and steady state RNA transcripts of Srebp1c, Lpl and ApoE were profiled relative
to Cyclophilin A by qRT-PCR. This represents results from an individual experiment per-
formed in duplicate. Error bars represent the range of the means.
(TIF)
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S3 Fig. Individual LXR/RXR ligand induction of Abca1 is less affected by PRMT2 levels.
BMDMs from wild type and Prmt2-/- mice were cultured in normal glucose, placed in 1% FBS
overnight and treated for four hours with DMSO, 5 μMT, 1 μM 9cisRA or both and expression
of Abca1 relative to Cyclophilin A was determined by qRT-PCR. This experiment represents a
single experiment performed in triplicate. Error bars represent SD of three technical replicates.
(TIF)
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